Elevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome
Version of Record online: 9 DEC 2005
Copyright © 1994 American College of Rheumatology
Arthritis & Rheumatism
Volume 37, Issue 11, pages 1593–1601, November 1994
How to Cite
Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., Lopez, Y. and Mackillip, F. (1994), Elevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome. Arthritis & Rheumatism, 37: 1593–1601. doi: 10.1002/art.1780371106
- Issue online: 9 DEC 2005
- Version of Record online: 9 DEC 2005
- Manuscript Accepted: 5 JUN 1994
- Manuscript Received: 30 NOV 1993
- Pfizer Central Research
Objective. To measure, and seek clinical correlates with, levels of substance P (SP) in the cerebrospinal fluid (CSF) of fibromyalgia syndrome (FMS) patients.
Methods. CSF from 32 FMS patients and 30 normal control subjects was tested for SP by radio-immunoassay. Clinical measures included tender point examination and standardized questionnaires.
Results. CSF SP levels were 3-fold higher in FMS patients than in normal controls (P < 0.001), but they correlated only weakly with tenderness found on examination.
Conclusion. SP is significantly elevated in FMS CSF, but other abnormalities must exist in FMS to more fully explain the symptoms.